REVIEW article
Front. Cell Dev. Biol.
Sec. Signaling
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1602649
This article is part of the Research TopicUnraveling the Role of Receptor Signaling in Tumorigenesis and Cancer TherapyView all 6 articles
Research progress of ECT2 and RhoA-related signaling pathways in gynecological tumors
Provisionally accepted
- 1The Second Affiliated Hospital of Fujian Medical University, Fujian Medical University, Fuzhou, China
- 2The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Epithelial Cell Transformation Factor 2 (ECT2) is highly expressed in a variety of cancers, including gynecological tumors. The mislocalization of ECT2 can abnormally activate Ras homolog family member A (RhoA) in the Ras homolog gene family (Rho) Guanine nucleotide Exchange Factor (GEF) family. Activated RhoA binds to Rho-associated protein kinase (ROCK), phosphorylates various target proteins, triggers a cascade reaction, regulates the functions of downstream proteins, and thereby plays an important role in the occurrence and development of tumors. This article reviews the roles of ECT2 and RhoA/ROCK signaling pathways in ovarian cancer, cervical cancer, and endometrial cancer, and summarizes and discusses the research progress of downstream molecules, transduction pathways, and mechanisms related to them. Through comprehensive analysis and summary of the current research results, it is revealed that the ECT2/RhoA/ROCK signaling pathway and related crosstalk pathways play an important role in the occurrence, development, and metastasis of gynecological tumors. This article aims to provide a basis for related research and offer relevant references for the treatment of gynecological tumors in the future.
Keywords: Ect2, RhoA, ROCK, ovarian cancer, cervical cancer, endometrial cancer
Received: 30 Mar 2025; Accepted: 18 Jun 2025.
Copyright: © 2025 Sheng, Liang, Wang, Zhou, Xie, Ke and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yumin Ke, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian Province, China
Zhuna Wu, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.